PHATHOM PHARMACEUTICALS, INC. (PHAT) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | 153.78M USD | Liabilities, Current |
| Cash and equivalents | 182.48M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | 7.71M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $153.78M | $182.48M | (m) | (m) | $7.71M | (m) |
| 2026-03-31 | (m) | $125.04M | $180.90M | (m) | (m) | $6.51M | (m) |
| 2025-12-31 | (m) | $132.04M | $129.97M | (m) | (m) | $5.52M | (m) |
| 2025-09-30 | (m) | $93.12M | $135.16M | (m) | (m) | $3.61M | (m) |
| 2025-06-30 | (m) | $91.82M | $149.57M | (m) | (m) | $3.43M | (m) |
| 2025-03-31 | (m) | $74.03M | $212.31M | (m) | (m) | $3.17M | (m) |
| 2024-12-31 | (m) | $85.73M | $297.26M | (m) | (m) | $3.21M | (m) |
| 2024-09-30 | (m) | $65.29M | $334.68M | (m) | (m) | $3.11M | (m) |
| 2024-06-30 | (m) | $47.01M | $276.24M | (m) | (m) | $2.18M | (m) |
| 2024-03-31 | (m) | $43.46M | $322.23M | (m) | (m) | $1.46M | (m) |
| 2023-12-31 | (m) | $38.78M | $381.39M | (m) | (m) | $1.21M | (m) |
| 2023-09-30 | (m) | $23.98M | $213.68M | (m) | (m) | $111.00K | (m) |
| 2023-06-30 | (m) | $21.55M | $248.85M | (m) | (m) | $111.00K | (m) |
| 2023-03-31 | (m) | $14.44M | $129.57M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $26.24M | $155.38M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $22.88M | $196.84M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $21.07M | $207.39M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $11.39M | $138.09M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $18.92M | $183.26M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $27.81M | $224.62M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $39.61M | $209.67M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $40.84M | $237.97M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $55.52M | $287.50M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $27.67M | $226.36M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $13.26M | $247.27M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $4.58M | $256.67M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $3.75M | $243.76M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $207.49M | $74.48M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $2.19M | $879.00K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |